Skip to main content
Premium Trial:

Request an Annual Quote

NIH Seeks Licensee or Collaborator for Drug Discovery Software

Premium

The National Institutes of Health is seeking licensees or collaborative partners for a software package developed by the National Institute on Aging for analyzing "extremely large experimental data sets in a simple yet multidimensional manner."

The software, called Omnimorph, "allows multidimensional investigation of any form of data including experimental datasets in biomedical science using either gene arrays or proteomics," according to the NIH's Office of Technology Transfer.

The software enables users to find "extremely subtle" correlated differences between experimental datasets in order to identify "far more drug- or disease-specific factors than other analytical methods currently used," NIH said.

Omnimorph was developed by Stuart Maudsley, a senior investigator at NIA.

The software has already been used to discover novel G protein-independent receptor-based pharmacotherapeutics, which also makes it "a simple and unbiased tool to detect novel and unexpected modes of GPCR-based drug actions," NIH said.

Further information about the software is available here.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.